DXR

Daxor Corporation · NASDAQ

Sector Miscellaneous
Industry Investment Trusts/Mutual Funds
Website daxor.com
Employees(FY) -
ISIN US2394671034

Performance

-1.28%

1W

-0.01%

1M

+11.44%

3M

+26.99%

6M

-0.52%

YTD

-25.91%

1Y

Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Advanced Technical Analysis

Technical Analysis of DXR 2024-05-10

Overview:

In analyzing the technical indicators for DXR over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

Moving Averages (MA): The 5-day MA has been consistently below the closing prices, ind...

See more ...

Recent News & Updates

2024-04-15 20:00
New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion(Globenewswire)
2024-04-14 20:00
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100 )(Globenewswire)
2024-04-09 20:00
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital(Globenewswire)
2024-03-31 20:00
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24(Globenewswire)
2024-03-27 22:38
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-24 20:00
Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics(Globenewswire)
2024-03-21 20:00
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024(Globenewswire)
2024-03-18 02:18
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders(Globenewswire)
2024-03-18 02:18
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023(Globenewswire)
2024-03-10 20:00
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base(Globenewswire)
2024-03-07 19:00
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients(Globenewswire)
2024-02-25 19:00
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference(Globenewswire)
2024-02-11 19:00
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions(Globenewswire)
2024-02-06 19:00
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts(Globenewswire)
2024-01-28 19:00
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting(Globenewswire)
2024-01-15 19:00
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress(Globenewswire)
2024-01-08 19:00
DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES(Globenewswire)
2024-01-01 19:30
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer(Globenewswire)
2023-11-12 19:00
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients(Globenewswire)
2023-11-08 19:00
Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume(Globenewswire)
2023-10-12 20:00
Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting(Globenewswire)
2023-10-10 20:00
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100 Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting(Globenewswire)
2023-10-03 20:00
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program(Globenewswire)
2023-09-26 20:00
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023(Globenewswire)
2023-09-25 20:00
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®)(Yahoo Finance)
2023-09-11 00:00
Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients(Yahoo Finance)
2023-09-06 21:15
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-28 04:15
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders(Yahoo Finance)
2023-08-28 04:05
Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023(Yahoo Finance)
2023-08-09 20:00
JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®(Yahoo Finance)

Page 1 of 4

previousnext